Repligen Co. (NASDAQ:RGEN) Shares Purchased by Bank of Montreal Can

Bank of Montreal Can boosted its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 34.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 49,568 shares of the biotechnology company's stock after acquiring an additional 12,816 shares during the quarter. Bank of Montreal Can owned about 0.09% of Repligen worth $7,233,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Champlain Investment Partners LLC raised its position in Repligen by 149.0% in the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company's stock worth $211,464,000 after purchasing an additional 850,345 shares during the period. Bank of New York Mellon Corp raised its position in Repligen by 21.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company's stock valued at $172,749,000 after purchasing an additional 237,884 shares in the last quarter. Conestoga Capital Advisors LLC lifted its holdings in shares of Repligen by 26.7% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company's stock worth $119,363,000 after buying an additional 199,322 shares during the period. Thrivent Financial for Lutherans grew its position in shares of Repligen by 6.1% during the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company's stock worth $95,037,000 after buying an additional 36,773 shares in the last quarter. Finally, New York State Common Retirement Fund increased its stake in shares of Repligen by 14.4% during the third quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company's stock valued at $84,387,000 after buying an additional 71,274 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on RGEN. Wolfe Research began coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a "peer perform" rating for the company. StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a research report on Friday, November 22nd. Wells Fargo & Company began coverage on shares of Repligen in a report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 target price for the company. Royal Bank of Canada reaffirmed an "outperform" rating and set a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. Finally, Benchmark reiterated a "hold" rating on shares of Repligen in a research note on Monday, August 5th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $190.25.

Repligen Price Performance

Shares of NASDAQ:RGEN traded down $1.96 during midday trading on Tuesday, hitting $148.50. The company's stock had a trading volume of 579,792 shares, compared to its average volume of 663,789. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $211.13. The company has a market cap of $8.32 billion, a P/E ratio of -401.34, a price-to-earnings-growth ratio of 4.53 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The business's 50 day simple moving average is $141.29 and its 200 day simple moving average is $142.10.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts' consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. During the same period last year, the company posted $0.23 EPS. The business's revenue was up 9.7% on a year-over-year basis. On average, analysts forecast that Repligen Co. will post 1.52 EPS for the current year.

Insider Buying and Selling at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. This represents a 13.70 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 1.20% of the stock is owned by company insiders.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.